Monoclonal Antibodies Treatment Based on its lack of activity against circulating COVID-19 variants, the U.S. Food & Drug Administration has withdrawn emergency use authorization (EUA) for bebtelovimab. There are currently no monoclonal antibody therapies authorized for the treatment of COVID-19.